Chuanliang Cui

6.3k total citations · 1 hit paper
151 papers, 2.9k citations indexed

About

Chuanliang Cui is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Chuanliang Cui has authored 151 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 73 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Chuanliang Cui's work include Cutaneous Melanoma Detection and Management (59 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Melanoma and MAPK Pathways (50 papers). Chuanliang Cui is often cited by papers focused on Cutaneous Melanoma Detection and Management (59 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Melanoma and MAPK Pathways (50 papers). Chuanliang Cui collaborates with scholars based in China, Ethiopia and United States. Chuanliang Cui's co-authors include Lu Si, Xinan Sheng, Zhihong Chi, Jun Guo, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Jie Dai and Xieqiao Yan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Chuanliang Cui

143 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Chuanliang Cui

Since Specialization

Citations

This map shows the geographic impact of Chuanliang Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuanliang Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuanliang Cui more than expected).

Fields of papers citing papers by Chuanliang Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuanliang Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuanliang Cui. The network helps show where Chuanliang Cui may publish in the future.

Co-authorship network of co-authors of Chuanliang Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Chuanliang Cui. A scholar is included among the top collaborators of Chuanliang Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuanliang Cui. Chuanliang Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma 2025 ·Cancer Management and Research ·Jiaran Zhang, (unknown), Lili Mao, Caili Li, Xiaoting Wei, Junjie Gu, Xuan Wang, Li Zhou, Bin Lian, (unknown), Xieqiao Yan, Siming Li, Chuanliang Cui, Zhihong Chi, (unknown), Jun Guo, Lu Si	1
2	Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study. 2024 ·Journal of Clinical Oncology ·Lili Mao, Jie Dai, Xue Bai, Yan Kong, (unknown), (unknown), Chuanliang Cui, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Siming Li, Li Zhou, (unknown), Juan Li, Caili Li, Rong Duan, Huayan Xu, (unknown), Lu Si	1
3	Natural history of bone-only metastasis in renal cell carcinoma 2024 ·Urologic Oncology Seminars and Original Investigations ·Bixia Tang, Rong Duan, (unknown), Xieqiao Yan, Siming Li, Li Zhou, Juan Li, Huayan Xu, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, (unknown), Caili Li, Chuanliang Cui, Lu Si, Zhihong Chi, Jun Guo, Xinan Sheng	1
4	Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma 2024 ·The Oncologist ·Bixia Tang, (unknown), Zhihong Chi, Rong Duan, Chuanliang Cui, Lu Si, Yixun Liu, Xuechun Hu, Zhi Liu, Ping Xiang, Siming Li, Xieqiao Yan, Li Zhou, Juan Li, (unknown), Xiaohui Yu, Xiangrong Dai, (unknown), Jun Guo, Xinan Sheng	2
5	Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study 2023 ·BMC Cancer ·Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, (unknown), Qing Xu, (unknown), Xuan Wang, (unknown), Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, (unknown), Qian Tan, Di Wu, Jun Guo	6
6	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma 2022 ·SHILAP Revista de lepidopterología ·Xu Xiao, Qian Guo, Chuanliang Cui, Yating Lin, Lei Zhang, (unknown), Qiyuan Li, (unknown), Wenxian Yang, Yan Kong, Rongshan Yu	18
7	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study 2022 ·Journal for ImmunoTherapy of Cancer ·Chuanliang Cui, Xuan Wang, Bin Lian, (unknown), Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert H.I. Andtbacka, (unknown)	38
8	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis 2022 ·Journal for ImmunoTherapy of Cancer ·Siming Li, Xiaowen Wu, Xieqiao Yan, Li Zhou, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Yan Kong, Xiongwen Tang, Hui Feng, Sheng Yao, Keith T. Flaherty, Jun Guo, Xinan Sheng	33
9	Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. 2022 ·Journal of Clinical Oncology ·Xinan Sheng, Li Zhou, Zhisong He, Hongqian Guo, Xieqiao Yan, Siming Li, Huayan Xu, Juan Li, (unknown), Lu Si, Chuanliang Cui, Lili Mao, Bin Lian, Bixia Tang, Xuan Wang, Xue Bai, (unknown)	20
10	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021 ·Journal for ImmunoTherapy of Cancer ·Xue Bai, Michelle Kim, Gyulnara G. Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley Fadden, Krista M. Rubin, Tatyana Sharova, Dennie T. Frederick, Keith T. Flaherty, Ryan J. Sullivan, Jun Guo, Genevieve M. Boland	8
11	EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma 2021 ·Journal of Investigative Dermatology ·Tianxiao Xu, Jie Dai, (unknown), (unknown), Lu Si, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Yan Kong, Jun Guo	26
12	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma 2021 ·Journal of Clinical Oncology ·Xieqiao Yan, Xinan Sheng, Zhihong Chi, Lu Si, Chuanliang Cui, Yan Kong, Bixia Tang, Lili Mao, Xuan Wang, Bin Lian, Siming Li, Xue Bai, Li Zhou, Jie Dai, Hong Yao, Jun Guo	36
13	Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma 2021 ·npj Genomic Medicine ·Chuanliang Cui, (unknown), Wenxian Yang, Zhihong Chi, Xinan Sheng, Lu Si, (unknown), Jinyu Yu, Shun Wang, Rongshan Yu, Jun Guo, Yan Kong	61
14	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images 2020 ·Translational Oncology ·Jing Hu, Chuanliang Cui, Wenxian Yang, Lihong Huang, Rongshan Yu, Si‐Yang Maggie Liu, Yan Kong	48
15	cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients 2018 ·Translational Cancer Research ·Tianxiao Xu, Sifan Yu, Meng Ma, Jie Dai, Zhihong Chi, Lu Si, Xinan Sheng, Chuanliang Cui, Yan Kong, Jun Guo	1
16	MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases 2017 ·Clinical Cancer Research ·Xue Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian, Xieqiao Yan, Li Zhou, Jie Dai, Jun Guo, Lu Si	72
17	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors 2015 ·Clinical Cancer Research ·Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo	58
18	Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib 2013 ·Clinical Cancer Research ·Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, Jun Guo	38
19	Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma 2013 ·Clinical Cancer Research ·Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, Jun Guo	121
20	Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma 2011 ·Clinical Cancer Research ·(unknown), Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lü, Jun Guo	181

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact